Gilead

Patients

Gilead's HIV success and controversy: Expanding access amid ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine.

Oncology

Ibrahim Elhoussieny and Warner Biddle at ASCO 2024

ASCO 2024 - Warner Biddle and Ibrahim Elhoussieny

ASCO is always an interesting show for Kite, the Gilead Sciences subsidiary focused on cell therapy.

R&D

4 years on: Remembering the COVID-19 pandemic

This year, Monday 11th March marked four years since the World Health Organization (WHO) declared COVID-19 a global pandemic.

News

Gilead, Arcus say TIGIT combo encouraging in GI cancer

Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy

Sales & Marketing

All eyes remain on US government patent dispute with Gilead

A high-stakes court battle is currently being fought in the US, with the government accusing a big pharma company of patent infringement for the first time.

News

NICE recommends first CAR-T cell therapy on NHS in England

Gilead Sciences and Kite, a Gilead company, have announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta (axicabtagene ciloleucel; axi-cel) for